Bli medlem
Bli medlem

Du är här


Hansa Medical: Hansa Medical appoints Henk Doude van Troostwijk as Vice President, Commercial Operations

Hansa Medical AB (publ) announced today the appointment of Henk Doude
van Troostwijk as Vice President, Commercial Operations to strengthen
its management team.

Henk's key focus will be on the company's commercial assessments of
its lead project IdeS, including market access, pricing and
re-imbursement aspects. IdeS is now in Phase II clinical development
focused on kidney transplantation in sensitized patients.

"We are very excited that Henk will engage in Hansa Medical, as we now
start to prepare our commercialization strategy for IdeS", said Göran
Arvidson, President and CEO of Hansa Medical.

Henk has significant management experience in sales and marketing from
the areas of transplantation and orphan drugs. Lately, Henk has
served as Business Unit Director Oncology and Transplantation at
Genzyme and most recently as General Manager of European Commercial
Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan
disease focused global biopharma company based in the US. Henk holds
an MBA from Henley Management College at the University of Reading,

Besides Henk, the management team of Hansa Medical consists of:
Göran Arvidson President and CEO
Christian Kjellman Senior Vice President, Research and Development
Emanuel Björne Vice President, Business Development and Investor Relations
Steven Glazer Vice President, Chief Medical Officer
Eva-Maria Joed Vice President, Chief Financial Officer
Lena Winstedt Vice President, Project Management

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel
immunomodulatory enzymes. The lead project IdeS is an
antibody-degrading enzyme in clinical development, with potential use
in transplantation and rare autoimmune diseases. Additional projects
focus on development of new antibody modulating enzymes, as well as
HBP, a diagnostic biomarker for prediction of severe sepsis at
emergency departments that is already introduced on the market. The
company is based in Lund, Sweden. Hansa Medical's share (ticker:
HMED) is listed on Nasdaq Stockholm.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.